Site Announcement
For the latest results and update on CytoDyn’s Phase 2 CRC trial and more, here’s a link to our April 30, 2026 investor update webinar
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 02/04/11 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
3 | |
| 01/25/11 | UPLOAD | SEC-generated letter |
|
2 | |
| 01/14/11 | 10-Q | Quarterly report pursuant to sections 13 or 15(d) |
|
27 | |
| 01/07/11 | 8-K | Current report filing |
|
4 | |
| 12/21/10 | 8-K | Current report filing |
|
4 | |
| 12/14/10 | 10-Q | Quarterly report pursuant to sections 13 or 15(d) |
|
24 | |
| 12/09/10 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 12/08/10 | 8-K | Current report filing |
|
4 | |
| 12/03/10 | 10-K | Annual report pursuant to section 13 and 15(d) |
|
44 | |
| 10/25/10 | 10-Q | Quarterly report pursuant to sections 13 or 15(d) |
|
26 |
